CAS NO: | 380623-76-7 |
包装 | 价格(元) |
5mg | 电议 |
25mg | 电议 |
Cas No. | 380623-76-7 |
别名 | SM-7368 |
化学名 | 3-chloro-4-nitro-N-(5-nitro-2-thiazolyl)-benzamide |
Canonical SMILES | ClC1=C([N+]([O-])=O)C=CC(C(NC2=NC=C([N+]([O-])=O)S2)=O)=C1 |
分子式 | C10H5ClN4O5S |
分子量 | 328.7 |
溶解度 | ≤100mg/ml in DMSO |
储存条件 | Store at 4℃ |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | NF-κB Activation Inhibitor III is a NF-κB inhibitor. NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) is a protein complex controling transcription of DNA, cytokine production as well as cell survival. NF-κB is found in nearly all animal cell types and is involved in cellular responses to stimuli such as cytokines, stress, free radicals, heavy metals, and bacterial or viral antigens. In vitro: Previous study found that NF-κB Activation Inhibitor III could inhibite TNF-a-induced MMP-9 upregulation in concentration-dependently and showed maximal activity at 10 μM. NF-κB Activation Inhibitor III also inhibited TNF-a-induced MMP-9 mRNA transcript accumulation and protein expression. It was also found that NF-κB Activation Inhibitor III strongly inhibited TNF-a-induced NF-jB activity but not AP-1 activity. In addition, NF-κB Activation Inhibitor III was able to strongly inhibit the TNF-a-induced invasion of HT1080 human fibrosarcoma cell line. These findings demonstrated that NF-κB Activation Inhibitor III was a synthetic compound inhibiting TNF-a-induced MMP-9 expression, and therefore NF-κB Activation Inhibitor III would be useful for the development of chemotherapy targeting TNF-a-mediated tumor invasion and metastasis [1]. NF-κB Activation Inhibitor III was used to disrupt NF-κB signaling to evaluate the role of syndecans in mediating extracellular matrix integrity [2]. In vivo: So far, there is no animal in vivo data reported. Clinical trial: Up to now, NF-κB Activation Inhibitor III is still in the preclinical development stage. References: |